Advanced Search
LI Zihuang, LI Xianming, YANG Dong, XU Gang, ZHOU Yayan, WU Shihai, LI Zhuangling. Clinical Analysis of Temozolomide Combined with Radiotherapy on High-grade Glioma[J]. Cancer Research on Prevention and Treatment, 2015, 42(02): 185-189. DOI: 10.3971/j.issn.1000-8578.2015.02.019
Citation: LI Zihuang, LI Xianming, YANG Dong, XU Gang, ZHOU Yayan, WU Shihai, LI Zhuangling. Clinical Analysis of Temozolomide Combined with Radiotherapy on High-grade Glioma[J]. Cancer Research on Prevention and Treatment, 2015, 42(02): 185-189. DOI: 10.3971/j.issn.1000-8578.2015.02.019

Clinical Analysis of Temozolomide Combined with Radiotherapy on High-grade Glioma

More Information
  • Received Date: October 13, 2014
  • Revised Date: December 18, 2014
  • Objective To observe the efficacy and safety of temozolomide(TMZ) combined with radiotherapy on patients with high-grade glioma(HGG), and to explore the prognostic factors for HGG patients. Methods We retrospectively analyzed the clinical data of 50 patients with newly diagnosed HGG treated with TMZ combined with radiotherapy. All patients were treated with three-dimensional conformal technique(3DCRT) or intensity-modulated radiotherapy(IMRT), and received oral TMZ[75 mg/(m2·d)] during radiotherapy; the adjuvant chemotherapy scheme TMZ[(150-200) mg/(m2·d)] for 5 days, 28 days as a cycle, was used after radiochemotherapy. We analyzed the clinical outcome and safety of those HGG patients. Multivariate analysis was used to analyze some factors related to prognostic significance, including gender, age, Karnovsky performance scores(KPS), excision degree, pathological grade, interval time between surgery and radiochemotherapy, radiotherapy techniques and adjuvant TMZ cycle number. Results With a median follow-up of 21.4 months (6.6-57.5 months), 28 patients had disease progression or recurrence, and 22 patients were dead. The 1-, 2-, 3-year overall survival(OS) and progression-free survival(PFS) rates were 85.8% and 71.8%, 54.9% and 44.2%, 51.2% and 44.2%, respectively. TMZ combined with radiotherapy was generally well tolerated and common side effects were nausea, vomiting, neutropenia and thrombocytopenia. Multivariate analysis showed that independently prognostic factors for OS were KPS, pathological grade and adjuvant TMZ cycles; those for PFS were excision degree, pathological grade and adjuvant TMZ cycle number. Conclusion TMZ combined with radiotherapy have good efficacy and safety on HGG patients. KPS, excision degree, pathological grade and adjuvant TMZ cycle number are the important prognostic factors for HGG patients.
  • [1]
    Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas, a clinical review[J]. JAMA, 2013, 310(17): 1842-50.
    [2]
    Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009[J]. Neuro Oncol, 20 12, 14 suppl 5: v1-49.
    [3]
    Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10): 987-96.
    [4]
    Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5- year analysis of the EORTC-NCIC trial[J]. Lancet Oncol, 2009, 10 (5): 459-66.
    [5]
    Oike T, Suzuki Y, Sugawara K, et al. Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results[J]. PLoS One, 2013, 8(11): e78943.
    [6]
    DeAngelis LM. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy[J]. J Clin Oncol, 2009, 27(35): 58 61-2.
    [7]
    Omar AI, Mason WP. Temozolomide: the evidence for its therapeutic efficacy in malignant astrocytoma[J]. Core Evid, 2010, 4: 93-111.
    [8]
    Dresemann G. Temozolomide in malignant glioma[J]. Onco Targets Ther, 2010, 3: 139-46.
    [9]
    Scoccianti S, Magrini SM, Ricardi U, et al. Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology)[J]. Neuro Oncol, 2012, 14(6): 798-807.
    [10]
    Zhang L, Wu X, Xu T, et al. Chemotherapy plus radiotherapy versus radiotherapy alone in patients with anaplastic glioma: a systematic review and meta-analysis[J]. J Cancer Res Clin Oncol, 20 13,139(5): 719-26.
    [11]
    Gutenberg A, Bock HC, Reifenberger G, et al. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis[J]. Acta Neurochir(Wien), 2013, 155(3): 429-35.
    [12]
    Valduvieco I, Verger E, Bruna J, et al. Impact of radiotherapy delay on survival in glioblastoma[J]. Clin Transl Oncol, 2013, 15 (4): 278-82.
    [13]
    Chen YD, Feng J, Fang T, et al. Effect of intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy on clinical outcomes in patients with glioblastoma multiforme[J]. Chin Med J(Engl), 2013, 126 (12): 2320-4.
    [14]
    Roldán Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme[J]. J Neurooncol, 2012, 108(1): 173-7.
    [15]
    Seiz M, Krafft U, Freyschlag CF, et al. Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution[J]. J Cancer Res Clin Oncol, 2010, 136(11): 1691-5.
  • Related Articles

    [1]LI Hongfei, TANG Weizhong, HUANG Qinglu, HUANG Kezeng, CAI Shangkun. Effect of Oxaliplatin on CD44V6, VEGF, survivin, Caspase-3 and Caspase-7 in Dimethylhydrazine-induced Colon Cancer Rats[J]. Cancer Research on Prevention and Treatment, 2015, 42(06): 560-563. DOI: 10.3971/j.issn.1000-8578.2015.06.006
    [2]Nie Yanli, Ruan Zhiping, Nan Kejun. Expressions of DR5,caspase-8,caspase-9 and caspase-3 in HepG2 Cell Line Treated with Gemcitabine[J]. Cancer Research on Prevention and Treatment, 2013, 40(02): 134-137. DOI: 10.3971/j.issn.1000-8578.2013.02.003
    [3]DING Hui, LI Xian-ming, GAO Yan, HU Li-xia, YANG Dong, ZHOU Ya-yan, XU Gang. Expression and Significance of HIF-2α and Caspase-3 in Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(01): 41-44. DOI: 10.3971/j.issn.1000-8578.2011.01.012
    [4]WANG Feng-qi, ZHAO Wei-ming, ZHANG Cheng, JIN Cheng-jun, ZHANG Zi-jian, ZHONG Zhao-hua, XIU You-cheng. Experimental of Combining Therapy with IL-12 Gene and THP in Bladder Cancer Nude Mice Model[J]. Cancer Research on Prevention and Treatment, 2010, 37(11): 1241-1244. DOI: 10.3971/j.issn.1000-8578.2010.11.008
    [5]WANG Ya-li, WANG Zhong-wei, WANG Xi-jing, JIN Ying-ying. Caspase-3 Gene of Mediating X radiation Induced Apoptosis in Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2009, 36(07): 541-544. DOI: 10.3971/j.issn.1000-8578.2009.07.001
    [6]ZHANG Xiao-Juan, WANG Na, ZHOU Rong-Miao, DONG Xiu-Juan, LI Yan. Correlation of MMP-12 Polymorphism to Risk of Squamous Cell Carcinoma and Gastric Cardiac Adenocarcinoma[J]. Cancer Research on Prevention and Treatment, 2008, 35(10): 740-743. DOI: 10.3971/j.issn.1000-8578.2861
    [7]WANG Yan-yan, SONG Xing-fu, CUI Xiang-jun, HUANG Ji. Apoptosis Induced by Artesunate in Human Adenocarcinoma Cell Line A549 Cells Associated with Activation of caspase-9 and caspase-3[J]. Cancer Research on Prevention and Treatment, 2007, 34(09): 651-653. DOI: 10.3971/j.issn.1000-8578.2020
    [8]HUANG Wen-fang, YANG Yong-chang, LIU Hua, CHEN Jiang, ZHOU Ding-an. Changes of Caspase-3 and Caspase-9 Activity during the Simvastatin-induced Apoptosis in K562 Cells[J]. Cancer Research on Prevention and Treatment, 2007, 34(01): 39-41. DOI: 10.3971/j.issn.1000-8578.1221
    [9]YE Shu-nan, YANG Shu-hua, YANG Chao, XU Wei-hua. A Tumor-targeted Vector for Interleukin-12 Gene Therapy to Enhance the Anti-osteosarcoma Immunity in Nude Mouse[J]. Cancer Research on Prevention and Treatment, 2005, 32(05): 305-307. DOI: 10.3971/j.issn.1000-8578.2424
    [10]YE Shu-nan, YANG Shu-hua, WU Qiang, YANG Cao, LI Jing, XU Wei-hua. Polythylenimine AS A Nonviral Vector for Murine Interleukin-12 Gene Transfer to the Mouse Osteosarcoma Cells[J]. Cancer Research on Prevention and Treatment, 2005, 32(02): 96-98. DOI: 10.3971/j.issn.1000-8578.693

Catalog

    Article views (1792) PDF downloads (834) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return